Clover Health (CLOV) Q4 2025 earnings review
Hyper-Growth Hits Margins Now, But Sets Up a Promised 2026 Inflection
Clover Health successfully executed its strategy to aggressively grab market share in 2025, driving full-year revenues up 40% to $1.9 billion. However, this growth came at a steep near-term cost. Q4 2025 saw Adjusted EBITDA reverse to a $23.3 million loss, while the Insurance Benefit Expense Ratio (BER) spiked to 95.0% due to the heavy influx of new, initially unprofitable members. Management views 2025 as the peak investment year and is strongly signaling a turnaround. Their 2026 guidance projects a monumental milestone: a return to $50M-$70M in Adjusted EBITDA and the company's first-ever full year of GAAP Net Income profitability.
🐂 Bull Case
The business model relies on a proven engine: new members cost more initially (negative $110 PMPM) but mature into highly profitable returning cohorts (positive $217 PMPM). The massive 2025 new member class will mature in 2026, driving a massive planned margin expansion.
Armed with an upcoming 4-Star payment year for its PPO plans, a favorable CMS rate environment, and operating leverage, guidance points to GAAP Net Income of up to $20 million in 2026.
🐻 Bear Case
The Q4 Insurance BER of 95.0% (97.2% normalized) is a severe deterioration from 82.8% a year ago. If cohort maturation is slower than expected or systemic utilization pressures persist, 2026 guidance will be at risk.
Total cash and investments dropped 27% year-over-year to $319.9 million. With the rapid acceleration of lives under management (154k-158k guided for 2026), the company has less margin for error before needing external funding.
⚖️ Verdict: ⚪
Neutral. The top-line execution and 2026 profitability guidance are exceptional. However, the steep Q4 margin collapse highlights the severe friction of their growth model. The stock's performance rests entirely on management's ability to seamlessly execute the planned 2026 margin recovery.
Key Themes
The Double-Edged Sword of Accelerated Growth
Clover successfully captured market share from retreating competitors, driving full-year membership up 38% to 113,803. However, this growth severely pressured the bottom line. Q4 Net Loss widened 129% to $49.3M, and Q4 Adjusted EBITDA reversed from a $7.8M profit in 24Q4 to a $23.3M loss. Management must now prove they can absorb an even larger projected growth wave in 2026 without breaking the balance sheet.
Clover Assistant & Cohort Economics
The core thesis remains that the Clover Assistant (CA) technology effectively manages chronic care. Management previously noted a ~700 basis point Medical Care Ratio (MCR) improvement from Year 1 to Year 2. The entire 2026 GAAP profitability forecast hinges on CA successfully bending the cost curve for the massive influx of 2025 new members.
4-Star Payment Year Tailwind
2026 represents a critical regulatory and financial inflection point. The transition from a 3.5-star to a 4-star rating for PPO plans (representing ~97% of members) provides a direct boost to benchmark revenue. This structural advantage acts as the primary bridge from 2025's losses to 2026's targeted GAAP profitability.
Exceptional SG&A Operating Leverage
Despite absorbing massive volume, Clover is exhibiting powerful scale economies. Adjusted SG&A dropped 410 basis points to 17.4% of Total Revenues for the full year 2025 (down from 21.5% in 2024). In Q4 specifically, Adjusted SG&A was 20.0%, an impressive 550 basis point improvement year-over-year.
Guidance Metric Obfuscation
A notable red flag in the latest release is a change in guidance disclosures. The company has stopped providing guidance for 'Insurance Revenue' and 'Insurance BER', replacing them with 'Total Revenues' and 'Consolidated Gross Profit'. Removing forward-looking BER guidance exactly when the metric is experiencing historic pressure (95.0% in Q4) decreases visibility into the core medical cost trajectory.
Declining Liquidity Buffer
Total cash, cash equivalents, and investments ended the year at $319.9 million, a steep 26.9% decline from $437.6 million a year ago. While management previously stated they intend to be 'self-funding', the combination of massive membership scaling, initial new-member unprofitability, and a shrinking cash pile leaves less room for execution errors.
Other KPIs
Accelerating. Up 40.3% year-over-year from $1.37B in 2024, driven entirely by the 38% increase in MA membership. Exceeded their mid-year guidance trajectory.
Decelerating. Down 69.0% from $70.1M in FY24. The entirety of this profit was generated in the first half of the year, before the Q3 and Q4 cost pressures from the maturing new member base dragged the back half into negative territory.
Guidance
Accelerating. At the $2.865B midpoint, this implies a massive 49% YoY growth rate, stepping up from the 40% growth seen in 2025. This reflects an industry-leading 53% YoY AEP growth.
Accelerating. Implies 46% growth YoY at the midpoint (an addition of ~49,000 average lives vs 2025). The company continues to capitalize on competitors pulling back from wide-network PPO plans.
Reversing. After compressing to $21.7M in 2025, guidance implies a sharp rebound to the $60M midpoint. This depends heavily on cohort maturation and the 4-star payment tailwind mitigating the negative margins of the 2026 new member class.
Reversing. This is the ultimate bull thesis milestone. If achieved, it would mark a massive inflection from the $85.5 million net loss in 2025, proving the underlying viability of the technology-first PPO model.
Key Questions
Cohort Economics Validation
With the Insurance BER spiking to 95% in Q4, are you seeing the expected 700 bps MCR improvement in the early 2025 cohort members now that they are crossing into their second year, or have systemic cost pressures altered that curve?
Transparency on BER Guidance
You have replaced Insurance BER guidance with Consolidated Gross Profit for 2026. Given the acute investor focus on medical cost trends, why remove the specific BER target, and what implicit BER is baked into the new Gross Profit range?
Capital Requirements for 2026 Growth
With cash and investments declining by $117M in 2025 to $320M, and 2026 membership growth accelerating even faster, at what point does the negative first-year cash drag of new members require you to seek external financing?
Counterpart Health Revenue
Counterpart Health continues to be framed as a major blue-ocean opportunity. Can you quantify the revenue contribution expected from this segment in the $2.8B+ total revenue guidance for 2026?